EA Pharma Presents Clinical Study Data of AJG533 and Pariet® in DDW2017

EA Pharma Co., Ltd. (President, Yuji Matsue; Headquarters, Chuo-ku, Tokyo, Japan) (hereinafter “EA Pharma”), a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, will present clinical study data for AJG533 in development for the treatment of chronic constipation (nonproprietary name: elobixibat hydrate, hereinafter “elobixibat”) and Pariet® (nonproprietary name: rabeprazole sodium, hereinafter “rabeprazole”) for use in the maintenance therapy of proton pump inhibitor-resistant reflux esophagitis in Digestive Disease Week (DDW) 2017, May 6th – 9th, 2017 in Chicago, Illinois, USA.

Elobixibat is a once-daily, orally available constipation treatment having a novel action mechanism, in-licensed from Albireo (Sweden). Elobixibat inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon, which is expected to improve the frequency of spontaneous bowel movements. EA Pharma has developed elobixibat for Japan with Mochida Pharmaceutical Co., Ltd. and filed the NDA in Japan in February 2017. The Phase II data included in the JNDA will be presented in DDW 2017.

For rabeprazole, Eisai Co., Ltd. filed the application in Japan seeking approval for additional dosage and administration of 10 mg twice-daily dosing for use in the maintenance therapy of proton pump inhibitor-resistant reflux esophagitis refractory to standard once daily regimen of proton pump inhibitor for 8 weeks in October 2016. The Phase III data included in the application for approval of additional dosage and administration will be presented in DDW 2017.

As a Japanese specialty pharma in the gastrointestinal disease area, EA Pharma stays close to patients and strives to make contributions to patients, their families and healthcare providers through development of pharmaceuticals from patient’s perspective.
The presentations about development and marketed products of EA Pharma accepted for DDW2017

<table>
<thead>
<tr>
<th>Product</th>
<th>Presentation title</th>
<th>Presentation date/time (Local Time)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elobixibat (AJG533)</td>
<td>[Abstract No.: 172] DETERMINING A CLINICAL OPTIMAL DOSE OF ELOBIXIBAT, A NOVEL IBAT INHIBITOR, IN JAPANESE PATIENTS WITH CHRONIC CONSTIPATION: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</td>
<td>Saturday, May 6th 16:00-16:12 Oral presentation</td>
</tr>
<tr>
<td>Rabeprazole (Pariet®)</td>
<td>[Abstract No.: Su1061] THE EFFICACY AND SAFETY OF RABEPRAZOLE 10MG TWICE DAILY IN MAINTENANCE THERAPY FOR REFLUX ESOPHAGITIS PATIENTS REFRACTORY TO STANDARD ONCE DAILY ADMINISTRATION OF PPI: THE JAPAN-BASED EXTEND STUDY</td>
<td>Sunday, May 7th 12:00-14:00 Poster presentation</td>
</tr>
</tbody>
</table>

End

Media Inquiries:
Corporate Planning Dept., EA Pharma Co., Ltd.
TEL : +81-(0)3-6280-9802
e-mail : contact_ea@eapharma.co.jp